Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic castration-resistant prostate cancer.
Data from the Phase 1/2 dose escalation and expansion trial show that ARV-766 was well-tolerated and demonstrated promising activity in a heavily pre-treated, post-NHA, all-comers patient population.
Across the Phase 1 and interim Phase 2 data, ARV-766 achieved a 42% PSA50 (reduction of 50% in prostate-specific antigen) in patients with AR LBD mutations.
Three of 5 patients with AR L702H mutations achieved PSA50; the three responding AR L702H patients had co-occur T878/H875 mutations.
Two of 4 RECIST-evaluable patients with tumors harboring AR LBD mutations had a best-observed response of partial response (1 confirmed partial response, one unconfirmed partial response).
ARV-766 has been well tolerated, and most treatment-related adverse events (TRAEs) have been Grade 1 or 2, with no Grade ≥4 TRAEs and no dose-limiting toxicities.
Price Action: ARVN shares are down 2.83% at $23.33 during the session on the last check Thursday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
